1-Boc-4-(4-Bromopyrazol-1-yl)piperidine CAS 877399-50-3 Purity ≥98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 1-Boc-4-(4-Bromopyrazol-1-yl)piperidine (CAS: 877399-50-3) with high quality, intermediate of Crizotinib (CAS: 877399-52-5). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Crizotinib Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 1-Boc-4-(4-Bromopyrazol-1-yl)piperidine |
| Synonyms | Crizotinib-D; tert-Butyl 4-(4-Bromopyrazol-1-yl)piperidine-1-Carboxylate; 4-(4-Bromopyrazol-1-yl)piperidine-1-Carboxylic Acid tert-Butyl Ester; 1-tert-Butoxycarbonyl-4-(4-Bromopyrazol-1-yl)piperidine; 1-(4-Boc-Piperidino)-4-Bromopyrazole; 1-Boc-4-(4-Bromo-1-Pyrazolyl)piperidine; 4-Bromo-1-(N-Boc-Piperidin-4-yl)-1H-Pyrazole; tert-butyl 4-(4-Bromo-1H-Pyrazol-1-yl)piperidine-1-Carboxylate; 1-(4-Boc-1-Piperidinyl)-4-Bromopyrazole; Crizotinib Impurity 4 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 877399-50-3 |
| Molecular Formula | C13H20BrN3O2 |
| Molecular Weight | 330.23 g/mol |
| Melting Point | 77.0 to 81.0℃ |
| Density | 1.43 |
| Solubility | Soluble in Methanol |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Crizotinib (CAS: 877399-52-5) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | White Solid | White Solid |
| Melting Point | 77.0 to 81.0℃ | Complies |
| Water by Karl Fischer | <0.50% | 0.11% |
| Purity / Analysis Method | ≥98.0% (HPLC) | 99.3% |
| 1H NMR Spectrum | Conforms to Structure | Complies |
| Mass | Conforms to Structure | Complies |
| Conclusion | The product has been tested & complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Hazard Symbols Xn - Harmful
Risk Codes 22 - Harmful if swallowed
1-Boc-4-(4-Bromopyrazol-1-yl)piperidine (CAS: 877399-50-3) is used as an intermediate of Crizotinib (CAS: 877399-52-5). Crizotinib (trade name Xalkori,) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy inanaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
In August 2011, the United States FDA approved Crizotinib (PF- 02341066) for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). Crizotinib is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When Crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, Crizotinib was found to inhibit RON (recepteur d'origine nantais) kinase with a 10-fold selectivity window over c-MET.
